NCT05281471Phase 3Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Study sponsor: Genelux Corporation

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-12Estimated
Enrollment · participants186Estimated
Source updated2026-08-26Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Jun 2026. After: Dec 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview